COVID-19: The experience from Iran

Daneshpazhooh, Maryam; Mahmoudi, Hamid Reza

doi:10.1016/j.clindermatol.2020.12.009

Cited by 13 publications

(9 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus spread rapidly worldwide, creating a deadly pandemic that has continued to this day (1). Iran was one of the first countries which faced the widespread outbreak of COVID-19 and has one of the highest mortality rates regarding the number of cases (2,3). The disease is asymptomatic or mild in most patients.…”

Section: Contextmentioning

confidence: 99%

Common Side Effects of COVID-19 Vaccines Used in Iran: A Review

Siahvoshi

Movahed

Ghods

2022

Ann Mil Health Sci Res

View full text Add to dashboard Cite

Context: Iran was one of the first countries in the world to encounter acute respiratory syndrome coronavirus 2 in February 2020. Numerous efforts have been made worldwide to develop safe and effective vaccines to prevent coronavirus disease 2019 (COVID-19). Finally, several vaccines with different platforms have been licensed for use in various countries. The injection of these vaccines can lead to a range of unwanted side effects (mild to severe). Objectives: This study tried to collect the common adverse effects of the most frequently used COVID-19 vaccines in Iran and provide readers with relevant information and statistics. Methods: This review study collected papers by searching in foreign journals using databases, such as PubMed, PubMed Central, MEDLINE, EBSCO, Google Scholar, and Embase, with the keywords of side effects, COVID-19, vaccine, AstraZeneca, Sputnik V, and Sinopharm, which were published within 2000-2021. Results: According to available information and studies, vaccines, unlike COVID-19, do not have any threatening and high-risk side effects, and their benefits outweigh their insignificant side effects. A total of 48 full-text studies and 10 valid websites with high citations and up-to-date information were selected. Among the relevant references, 26, 16, and 16 studies performed on AstraZeneca, Sputnik V, and Sinopharm vaccines were chosen for review, respectively. Conclusions: The findings of this study can reassure readers and be effective in combating misconceptions about vaccination. Undoubtedly, the main solution to overcome the economic damage and social health burden caused by the COVID-19 pandemic is to accelerate global vaccination.

show abstract

Section: Contextmentioning

confidence: 99%

Common Side Effects of COVID-19 Vaccines Used in Iran: A Review

Siahvoshi

Movahed

Ghods

2022

Ann Mil Health Sci Res

View full text Add to dashboard Cite

show abstract

“…Additionally, dermatology residents reached out to high-risk patients via phone call and these check-ins were deeply appreciated by patients. Nevertheless, the absence of an established technical and legal infrastructure to support TD has undermined the utility of TD in Iran [39]. From Saudi Arabia, Kaliyadan et al [40] recognized a very important cultural limitation to TD: patients, especially female, may not be comfortable with TD consultations for cultural/religious reasons.…”

Section: Perspectives Of Underserved Communities and Developing Nationsmentioning

confidence: 99%

Teledermatology During COVID-19: An Updated Review

2021

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has fundamentally transformed the landscape of providing dermatologic care. In an age of lockdowns and social distancing, teledermatology (TD) has emerged as a powerful tool to deliver remote care. Here, we review literature on TD use during the pandemic to evaluate the positives and negatives of TD implementation. We especially consider the reception of TD in underserved communities and the developing world as well as the ethico-legal challenges wrought by the burgeoning utilization of this new paradigm of care. The potential of TD to occupy a more prominent role in dermatologic care in a post-COVID-19 world is also discussed.

show abstract

“…1 The pandemic is still ongoing across the globe and causes a spectrum of manifestations from subclinical infection to death. 2 …”

Section: Introductionmentioning

confidence: 99%

Adverse outcome and severity of COVID ‐19 in patients with autoimmune bullous diseases: A historical cohort study

Moghadam

Kianfar

Dasdar

et al. 2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

The ongoing COVID‐19 pandemic has raised concerns regarding the outcome of this infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs used to treat these disorders. This investigation was performed from the onset of the pandemic to June 1, 2021. Patients with AIBDs who contracted COVID‐19 were evaluated. A generalized linear model was employed to find the predictors of severe COVID‐19 among patients with AIBDs. Ninety‐three patients with AIBDs with a mean age of 50.3 years were evaluated. The most COVID‐19 related symptoms were tiredness (76.3%) myalgia (69%), and cough (63.4%). During follow‐up, the rate of hospitalization and death were 45.2% and 4.3%, respectively. Previous comorbidities (β = 0.61) and mean prednisolone dosage above 10 mg/day in the last 3 months ( β = 1.10) significantly increased COVID‐19 severity. Also, vaccination against SARS‐CoV‐2 ( β = −1.50) and each passing month from the last rituximab dose decreased severity ( β = −0.02). Notably, 19.3% of the patients developed AIBD flare‐ups following COVID‐19 infection. Higher prednisone dose and the shorter interval from the last rituximab infusion were determinants of severe COVID‐19. Physicians should assess the risk versus the benefits when prescribing the medications. Moreover, vaccination could successfully attenuate COVID‐19 severity.

show abstract

COVID-19: The experience from Iran

Cited by 13 publications

References 111 publications

Common Side Effects of COVID-19 Vaccines Used in Iran: A Review

Common Side Effects of COVID-19 Vaccines Used in Iran: A Review

Teledermatology During COVID-19: An Updated Review

Adverse outcome and severity of COVID ‐19 in patients with autoimmune bullous diseases: A historical cohort study

Contact Info

Product

Resources

About